- Home
- BOLT vs NXTC Comparison
BOLT vs NXTC Comparison
Compare BOLT & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOLT
- NXTC
- Stock Information
- Founded
- BOLT 2015
- NXTC 2015
- Country
- BOLT United States
- NXTC United States
- Employees
- BOLT N/A
- NXTC N/A
- Industry
- BOLT Biotechnology: Pharmaceutical Preparations
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- BOLT Health Care
- NXTC Health Care
- Exchange
- BOLT Nasdaq
- NXTC Nasdaq
- Market Cap
- BOLT 22.6M
- NXTC 23.0M
- IPO Year
- BOLT 2021
- NXTC 2019
- Fundamental
- Price
- BOLT $0.51
- NXTC $0.79
- Analyst Decision
- BOLT Hold
- NXTC Strong Buy
- Analyst Count
- BOLT 5
- NXTC 2
- Target Price
- BOLT $1.25
- NXTC $4.00
- AVG Volume (30 Days)
- BOLT 186.2K
- NXTC 201.3K
- Earning Date
- BOLT 11-12-2024
- NXTC 11-07-2024
- Dividend Yield
- BOLT N/A
- NXTC N/A
- EPS Growth
- BOLT N/A
- NXTC N/A
- EPS
- BOLT N/A
- NXTC N/A
- Revenue
- BOLT $9,779,000.00
- NXTC N/A
- Revenue This Year
- BOLT $9.87
- NXTC N/A
- Revenue Next Year
- BOLT N/A
- NXTC N/A
- P/E Ratio
- BOLT N/A
- NXTC N/A
- Revenue Growth
- BOLT 35.86
- NXTC N/A
- 52 Week Low
- BOLT $0.48
- NXTC $0.76
- 52 Week High
- BOLT $1.56
- NXTC $2.57
- Technical
- Relative Strength Index (RSI)
- BOLT 41.39
- NXTC 36.33
- Support Level
- BOLT $0.50
- NXTC $0.76
- Resistance Level
- BOLT $0.55
- NXTC $0.83
- Average True Range (ATR)
- BOLT 0.04
- NXTC 0.07
- MACD
- BOLT -0.00
- NXTC 0.01
- Stochastic Oscillator
- BOLT 13.04
- NXTC 14.87
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.